135 related articles for article (PubMed ID: 24970482)
1. Heparanase cooperates with Ras to drive breast and skin tumorigenesis.
Boyango I; Barash U; Naroditsky I; Li JP; Hammond E; Ilan N; Vlodavsky I
Cancer Res; 2014 Aug; 74(16):4504-14. PubMed ID: 24970482
[TBL] [Abstract][Full Text] [Related]
2. Significance of host heparanase in promoting tumor growth and metastasis.
Zhang GL; Gutter-Kapon L; Ilan N; Batool T; Singh K; Digre A; Luo Z; Sandler S; Shaked Y; Sanderson RD; Wang XM; Li JP; Vlodavsky I
Matrix Biol; 2020 Nov; 93():25-42. PubMed ID: 32534153
[TBL] [Abstract][Full Text] [Related]
3. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.
Baker AB; Gibson WJ; Kolachalama VB; Golomb M; Indolfi L; Spruell C; Zcharia E; Vlodavsky I; Edelman ER
J Am Coll Cardiol; 2012 Apr; 59(17):1551-60. PubMed ID: 22516446
[TBL] [Abstract][Full Text] [Related]
4. Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.
Bhattacharya U; Gutter-Kapon L; Kan T; Boyango I; Barash U; Yang SM; Liu J; Gross-Cohen M; Sanderson RD; Shaked Y; Ilan N; Vlodavsky I
Cancer Res; 2020 Jan; 80(1):57-68. PubMed ID: 31690669
[TBL] [Abstract][Full Text] [Related]
5. Heparanase enhances myeloma progression via CXCL10 downregulation.
Barash U; Zohar Y; Wildbaum G; Beider K; Nagler A; Karin N; Ilan N; Vlodavsky I
Leukemia; 2014 Nov; 28(11):2178-87. PubMed ID: 24699306
[TBL] [Abstract][Full Text] [Related]
6. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.
Caruana I; Savoldo B; Hoyos V; Weber G; Liu H; Kim ES; Ittmann MM; Marchetti D; Dotti G
Nat Med; 2015 May; 21(5):524-9. PubMed ID: 25849134
[TBL] [Abstract][Full Text] [Related]
7. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients.
Nadir Y; Sarig G; Axelman E; Meir A; Wollner M; Shafat I; Hoffman R; Brenner B; Vlodavsky I; Haim N
Thromb Res; 2014 Sep; 134(3):639-42. PubMed ID: 25065557
[TBL] [Abstract][Full Text] [Related]
8. Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy.
Shteingauz A; Boyango I; Naroditsky I; Hammond E; Gruber M; Doweck I; Ilan N; Vlodavsky I
Cancer Res; 2015 Sep; 75(18):3946-57. PubMed ID: 26249176
[TBL] [Abstract][Full Text] [Related]
9. The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.
Hammond E; Khurana A; Shridhar V; Dredge K
Front Oncol; 2014; 4():195. PubMed ID: 25105093
[TBL] [Abstract][Full Text] [Related]
10. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.
Hermano E; Meirovitz A; Meir K; Nussbaum G; Appelbaum L; Peretz T; Elkin M
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25326645
[TBL] [Abstract][Full Text] [Related]
11. Nuclear localization of heparanase 2 (Hpa2) attenuates breast carcinoma growth and metastasis.
Hilwi M; Shulman K; Naroditsky I; Feld S; Gross-Cohen M; Boyango I; Soboh S; Vornicova O; Farhoud M; Singh P; Bar-Sela G; Goldberg H; Götte M; Sharrocks AD; Li Y; Sanderson RD; Ilan N; Vlodavsky I
Cell Death Dis; 2024 Mar; 15(3):232. PubMed ID: 38519456
[TBL] [Abstract][Full Text] [Related]
12. Nano drug delivery systems improve metastatic breast cancer therapy.
Zhu R; Lang T; Yin Q; Li Y
Med Rev (2021); 2021 Dec; 1(2):244-274. PubMed ID: 37724299
[TBL] [Abstract][Full Text] [Related]
13. Heparanase-A single protein with multiple enzymatic and nonenzymatic functions.
Vlodavsky I; Kayal Y; Hilwi M; Soboh S; Sanderson RD; Ilan N
Proteoglycan Res; 2023 Jul; 1(3):e6. PubMed ID: 37547889
[TBL] [Abstract][Full Text] [Related]
14. Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma.
Jayatilleke KM; Duivenvoorden HM; Ryan GF; Parker BS; Hulett MD
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297024
[TBL] [Abstract][Full Text] [Related]
15. Heparanase-1: From Cancer Biology to a Future Antiviral Target.
Lebsir N; Zoulim F; Grigorov B
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680276
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
[TBL] [Abstract][Full Text] [Related]
17. 4-O-Substituted Glucuronic Cyclophellitols are Selective Mechanism-Based Heparanase Inhibitors.
Borlandelli V; Armstrong Z; Nin-Hill A; Codée JDC; Raich L; Artola M; Rovira C; Davies GJ; Overkleeft HS
ChemMedChem; 2023 Feb; 18(4):e202200580. PubMed ID: 36533564
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix in skin diseases: The road to new therapies.
Malta MD; Cerqueira MT; Marques AP
J Adv Res; 2023 Sep; 51():149-160. PubMed ID: 36481476
[TBL] [Abstract][Full Text] [Related]
19. Non-enzymatic heparanase enhances gastric tumor proliferation via TFEB-dependent autophagy.
Yang M; Tang B; Wang S; Tang L; Wen D; Vlodavsky I; Yang SM
Oncogenesis; 2022 Aug; 11(1):49. PubMed ID: 35970822
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
